Publications by authors named "Murray D Norris"

100Publications

Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in CRLF2-Rearranged Ph-like ALL.

Mol Cancer Res 2020 Aug 14. Epub 2020 Aug 14.

Children's Cancer Institute, School of Women's and Children's Health, UNSW Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-19-1098DOI Listing
August 2020

Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression.

Cancer Res 2020 Sep 10;80(17):3706-3718. Epub 2020 Jul 10.

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-19-3914DOI Listing
September 2020

Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia.

Cancer Cell 2020 Aug 18;38(2):263-278.e6. Epub 2020 Jun 18.

Cancer and Stem Cell Biology Group, Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2052, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2020.05.014DOI Listing
August 2020

CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth.

Biochem Pharmacol 2020 02 17;172:113770. Epub 2019 Dec 17.

Children's Cancer Institute Australia, Lowy Cancer Research Centre, UNSW Sydney, Kensington, NSW, Australia; School of Women's and Children's Health, UNSW Sydney, Kensington, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2019.113770DOI Listing
February 2020

MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells.

Biochem Pharmacol 2019 10 11;168:237-248. Epub 2019 Jul 11.

Children's Cancer Institute Australia, Lowy Cancer Research Centre, UNSW Sydney, Kensington, NSW 2052, Australia; School of Women's and Children's Health, UNSW Sydney, Kensington, NSW 2052, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2019.07.009DOI Listing
October 2019

miR-101 suppresses the development of -rearranged acute myeloid leukemia.

Haematologica 2019 07 21;104(7):e296-e299. Epub 2019 Feb 21.

Cancer and Stem Cell Biology Group, Children's Cancer Institute, University of New South Wales, Sydney, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.209437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601101PMC
July 2019

JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.

Leukemia 2019 06 8;33(6):1400-1410. Epub 2019 Jan 8.

Cancer and Stem Cell Biology Group, Children's Cancer Institute, University of New South Wales, Sydney, NSW 2052, Australia.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-018-0354-z
Publisher Site
http://dx.doi.org/10.1038/s41375-018-0354-zDOI Listing
June 2019

Too many targets, not enough patients: rethinking neuroblastoma clinical trials.

Nat Rev Cancer 2018 06;18(6):389-400

Children's Cancer Institute Australia, Lowy Cancer Research Centre, UNSW Sydney, Kensington, NSW, Australia.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41568-018-0003-x
Publisher Site
http://dx.doi.org/10.1038/s41568-018-0003-xDOI Listing
June 2018

A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.

Cancer Res 2017 02 6;77(4):971-981. Epub 2016 Dec 6.

Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales Australia, Kensington, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2906DOI Listing
February 2017

ABC transporters as mediators of drug resistance and contributors to cancer cell biology.

Drug Resist Updat 2016 05 17;26:1-9. Epub 2016 Mar 17.

Children's Cancer Institute Australia, Lowy Cancer Research Centre, Randwick, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drup.2016.03.001DOI Listing
May 2016

Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.

Clin Cancer Res 2016 Sep 24;22(17):4391-404. Epub 2016 Mar 24.

Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2539DOI Listing
September 2016

Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.

Mol Oncol 2016 06 2;10(6):866-78. Epub 2016 Mar 2.

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Randwick 2031, Australia; Kids Cancer Centre, Sydney Children's Hospital, Randwick 2031, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2016.02.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423163PMC
June 2016

High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients.

Cancer Lett 2016 May 20;374(2):315-23. Epub 2016 Feb 20.

Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick 2031, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2016.02.021DOI Listing
May 2016

Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.

Oncotarget 2016 Feb;7(6):6353-68

QIMR Berghofer Medical Research Institute, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.7047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872719PMC
February 2016

Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.

Transl Pediatr 2015 Jul;4(3):226-38

1 Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, USA ; 2 Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA ; 3 Children's Cancer Institute Australia, Sydney, Australia ; 4 Lankenau Institute for Medical Research, Wynnewood, USA ; 5 Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2224-4336.2015.04.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729051PMC
July 2015

Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Mol Oncol 2015 Aug 29;9(7):1484-500. Epub 2015 Apr 29.

Children's Cancer Institute Australia, University of New South Wales, Sydney, Australia; Kids Cancer Centre, Sydney Children's Hospital, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2015.04.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528804PMC
August 2015

ABC transporters and neuroblastoma.

Adv Cancer Res 2015 8;125:139-70. Epub 2015 Jan 8.

Lowy Cancer Research Centre, Children's Cancer Institute, University of New South Wales, Sydney, New South Wales, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2014.10.005DOI Listing
October 2015

Folate pathway gene polymorphisms, maternal folic acid use, and risk of childhood acute lymphoblastic leukemia.

Cancer Epidemiol Biomarkers Prev 2015 Jan 13;24(1):48-56. Epub 2014 Nov 13.

Sax Institute, Haymarket, New South Wales, Australia. Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-14-0680DOI Listing
January 2015

GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis.

Blood 2014 Nov 7;124(22):3284-94. Epub 2014 Oct 7.

Cancer and Stem Cell Biology Group, Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia; School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-10-532523DOI Listing
November 2014

ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

J Natl Cancer Inst 2014 Jul 23;106(7). Epub 2014 Jun 23.

Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju149DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110473PMC
July 2014

Molecular profiling of childhood cancer: Biomarkers and novel therapies.

BBA Clin 2014 Jun 28;1:59-77. Epub 2014 Jun 28.

Children's Cancer Research Unit, Kids Research Institute, Westmead 2145, New South Wales, Australia ; The University of Sydney Discipline of Paediatrics and Child Health, The Children's Hospital at Westmead, Westmead 2145, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbacli.2014.06.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633945PMC
June 2014

ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma.

Front Oncol 2012 19;2:178. Epub 2012 Dec 19.

Experimental Therapeutics Program, Lowy Cancer Research Centre, Children's Cancer Institute Australia for Medical Research, University of New South Wales and Sydney Children's Hospital Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2012.00178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526013PMC
December 2012

Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma.

Front Oncol 2012 16;2:162. Epub 2012 Nov 16.

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2012.00162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499881PMC
November 2012

Prognostic significance of promoter DNA methylation in patients with childhood neuroblastoma.

Clin Cancer Res 2012 Oct 28;18(20):5690-700. Epub 2012 Aug 28.

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-0294DOI Listing
October 2012

N-Myc regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma.

Cancer Res 2012 Feb 27;72(4):845-53. Epub 2011 Dec 27.

Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, Randwick, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-1885DOI Listing
February 2012

ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.

J Natl Cancer Inst 2011 Aug 28;103(16):1236-51. Epub 2011 Jul 28.

Experimental Therapeutics and Molecular Diagnostics Program, Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, P.O. Box 81, Randwick, NSW 2031, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djr256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156802PMC
August 2011

ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript.

Pharmacogenet Genomics 2011 May;21(5):270-9

Children's Cancer Institute Australia for Medical Research, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0b013e328343dd5fDOI Listing
May 2011

ABC transporters in cancer: more than just drug efflux pumps.

Nat Rev Cancer 2010 02 15;10(2):147-56. Epub 2010 Jan 15.

Children's Cancer Institute Australia for Medical Research, Lowry Cancer Research Centre, University of New South Wales, P.O. BOX 151, Randwick NSW 2031, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc2789DOI Listing
February 2010

Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation.

J Biol Chem 2010 Feb 10;285(6):3561-7. Epub 2009 Dec 10.

Children's Cancer Institute Australia, Sydney Children's Hospital, Sydney, New South Wales 2031, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M109.053041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823496PMC
February 2010

Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol.

J Med Chem 2009 Oct;52(20):6209-16

UNSW Cancer Research Centre, University of New South Wales, Sydney 2052, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm9008339DOI Listing
October 2009

The cyclin-dependent kinase inhibitor, p21(WAF1), promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells.

Carcinogenesis 2009 Nov 22;30(11):1865-71. Epub 2009 Sep 22.

Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney 2031, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgp225DOI Listing
November 2009

Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.

Eur J Cancer 2009 Jul 1;45(10):1846-54. Epub 2009 Apr 1.

Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S095980490900172
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2009.03.002DOI Listing
July 2009

Mechanism of relapse in pediatric acute lymphoblastic leukemia.

Cell Cycle 2008 May 29;7(10):1315-20. Epub 2008 Feb 29.

Children's Cancer Institute Australiafor Medical Research, Experimental Therapeutics Program, PO Box 81 (HighSt), Randwick, Sydney, NSW 2031 Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.7.10.5885DOI Listing
May 2008

Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.

Proc Natl Acad Sci U S A 2007 Nov 14;104(47):18682-7. Epub 2007 Nov 14.

Children's Cancer Institute Australia for Medical Research and Centre for Children's Cancer and Blood Disorders, Sydney Children's Hospital, High Street, Randwick, Sydney, New South Wales 2031, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0705524104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2141837PMC
November 2007

p53 determines multidrug sensitivity of childhood neuroblastoma.

Cancer Res 2007 Nov;67(21):10351-60

Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-4345DOI Listing
November 2007

Enhancing the anti-angiogenic action of histone deacetylase inhibitors.

Mol Cancer 2007 Oct 25;6:68. Epub 2007 Oct 25.

The Children's Cancer Institute Australia for Medical Research, The University of New South Wales, Sydney, NSW 2031, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-6-68DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2173905PMC
October 2007

Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma.

Pharmacogenet Genomics 2007 Sep;17(9):709-17

Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=01213011-200709000-000
Publisher Site
http://dx.doi.org/10.1097/FPC.0b013e3280e1cc92DOI Listing
September 2007

The role of the multidrug resistance-associated protein 1 gene in neuroblastoma biology and clinical outcome.

Cancer Lett 2005 Oct;228(1-2):241-6

Children's Cancer Institute Australia for Medical Research, P.O. Box 81 Randwick, Sydney, NSW 2031, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2005.01.060DOI Listing
October 2005

Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.

J Clin Oncol 2005 Apr;23(10):2264-71

Centre for Children's Cancer and Blood Disorders, Sydney Children's Hospital, High St, Randwick, Sydney, NSW 2031, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.04.012DOI Listing
April 2005

Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs.

Mol Cancer Ther 2004 Sep;3(9):1137-46

Children's Cancer Institute Australia for Medical Research, High Street, P.O. Box 81, Randwick, New South Wales 2031, Australia.

View Article

Download full-text PDF

Source
September 2004

Regions syntenic to human 17q are gained in mouse and rat neuroblastoma.

Genes Chromosomes Cancer 2004 Jun;40(2):158-63

Institute of Human Genetics, International Centre for Life, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20031DOI Listing
June 2004

MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.

Oncogene 2004 Jan;23(3):753-62

The Robert H Lurie Comprehensive Cancer Center, Northwestern University's Feinberg School of Medicine, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1207151DOI Listing
January 2004

Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions.

Chem Biol 2003 Jul;10(7):597-607

Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, 2031, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1074-5521(03)00141-8DOI Listing
July 2003

The p53 pathway and its inactivation in neuroblastoma.

Cancer Lett 2003 Jul;197(1-2):93-8

Cancer Research Unit, The Medical School, University of Newcastle, Newcastle-upon-Tyne NE2 4HH, UK.

View Article

Download full-text PDF

Source
http://ac.els-cdn.com/S0304383503000880/1-s2.0-S030438350300
Web Search
http://search.proquest.com/openview/29c6d95b12d526bdda403463
Web Search
http://dx.doi.org/10.1016/s0304-3835(03)00088-0DOI Listing
July 2003